TANDEM DIABETES CARE INC·4

May 22, 4:04 PM ET

Cha Myoungil 4

Research Summary

AI-generated summary

Updated

Tandem Diabetes (TNDM) Director Cha Myoungil Receives RSU Award & Vesting

What Happened

  • Director Cha Myoungil received a grant of 10,220 restricted stock units (RSUs) on May 20, 2026 (reported as an award/derivative acquisition). The filing also reports that 8,759 RSUs vested/converted into shares on May 21, 2026 (reported as a derivative exercise/conversion), with a corresponding reported disposition of the same 8,759 shares on May 21, 2026. All transactions are reported at $0.00 per share (typical for RSU vesting/conversion).

Key Details

  • Transaction dates: May 20, 2026 (grant of 10,220 RSUs); May 21, 2026 (conversion/vesting of 8,759 RSUs and a matching disposition).
  • Prices: $0.00 per share for the RSU award and the conversion entries (RSUs convert to shares without an exercise price).
  • Shares owned after transaction: Not disclosed in this Form 4.
  • Footnotes of note:
    • F1: Each RSU represents a contingent right to receive one share or cash in lieu, per the 2023 Long-Term Incentive Plan.
    • F2: The 10,220 RSUs granted May 20, 2026 will vest on the one‑year anniversary, subject to plan terms.
    • F3: The 8,759 RSUs referenced were a prior grant (May 21, 2025) that vested and converted on the one‑year anniversary (May 21, 2026).
  • Filing timeliness: Form filed May 22, 2026; no late filing flag indicated.

Context

  • These entries relate to RSU awards and the one‑year vesting/settlement of previously granted RSUs — a routine form of equity compensation for directors and employees. The filing shows both conversion/acquisition of shares from vested RSUs and a simultaneous disposition of the same number of shares; filings sometimes show dispositions for tax withholding or net settlement, but this Form 4 does not specify the reason. This is not an open‑market buy or sell that directly signals a trading decision.

Loading document...